Eton Pharmaceutcials Inc (ETON)

$14.34 +0.26 (1.85%)
Market Cap 384.57M
Revenue (ttm) 39.01M
Net Income (ttm) -3.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 32.74
Profit Margin -9.79%
Debt to Equity Ratio 1.22
Volume 257,200
Avg Vol 253,268
Day's Range N/A - N/A
Shares Out 26.82M
Stochastic %K 95%
Beta 1.34
Analysts Strong Sell
Price Target $27.67

Latest News on ETON

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

Apr 1, 2025, 7:00 AM EDT - 20 days ago

Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Mar 25, 2025, 2:30 AM EDT - 27 days ago

CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program

Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:42 PM EDT - 4 weeks ago

Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Mar 18, 2025, 6:50 AM EDT - 4 weeks ago

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Mar 14, 2025, 6:50 AM EDT - 5 weeks ago

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Mar 4, 2025, 10:00 AM EST - 6 weeks ago

Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Mar 4, 2025, 6:50 AM EST - 6 weeks ago

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Mar 3, 2025, 6:50 AM EST - 7 weeks ago

Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Feb 7, 2025, 6:50 AM EST - 2 months ago

Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Feb 6, 2025, 6:50 AM EST - 2 months ago

Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Jan 3, 2025, 6:50 AM EST - 3 months ago

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Dec 20, 2024, 6:50 AM EST - 4 months ago

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Dec 3, 2024, 6:50 AM EST - 4 months ago

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Nov 25, 2024, 6:50 AM EST - 5 months ago

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:01 PM EST - 5 months ago

Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 5 months ago

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Nov 6, 2024, 4:30 PM EST - 5 months ago

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Oct 3, 2024, 6:30 AM EDT - 7 months ago

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 22, 2024, 4:30 PM EDT - 8 months ago

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript

Aug 11, 2024, 8:15 AM EDT - 9 months ago

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 9 months ago

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 30, 2024, 5:30 PM EDT - 9 months ago

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Jul 15, 2024, 4:05 PM EDT - 9 months ago

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript

May 11, 2024, 9:34 AM EDT - 1 year ago

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

May 9, 2024, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

May 1, 2024, 4:05 PM EDT - 1 year ago

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Apr 29, 2024, 4:30 PM EDT - 1 year ago

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

Mar 22, 2024, 2:20 AM EDT - 1 year ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

Mar 22, 2024, 2:00 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

Mar 14, 2024, 9:38 PM EDT - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 14, 2024, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

Feb 29, 2024, 4:01 PM EST - 1 year ago

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

Feb 21, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Feb 2, 2024, 6:50 AM EST - 1 year ago

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

Eton Pharmaceuticals, Inc. (ETON) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 5:18 PM EST - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Q3 2023 Earnings Call Transcript

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:01 PM EST - 1 year ago

Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Oct 30, 2023, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

Oct 4, 2023, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone

Eton Pharmaceuticals: Fading The Rally

Sep 11, 2023, 3:29 PM EDT - 1 year ago

Eton Pharmaceuticals: Fading The Rally

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 23, 2023, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Eton Pharmaceuticals, Inc. (ETON) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 8:32 PM EDT - 1 year ago

Eton Pharmaceuticals, Inc. (ETON) Q2 2023 Earnings Call Transcript

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

Aug 10, 2023, 4:01 PM EDT - 1 year ago

Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results

Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Aug 1, 2023, 4:05 PM EDT - 1 year ago

Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

Jun 28, 2023, 6:50 AM EDT - 1 year ago

Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection

Eton Pharmaceuticals, Inc. (ETON) Q1 2023 Earnings Call Transcript

May 11, 2023, 7:04 PM EDT - 2 years ago

Eton Pharmaceuticals, Inc. (ETON) Q1 2023 Earnings Call Transcript

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

May 11, 2023, 4:01 PM EDT - 2 years ago

Eton Pharmaceuticals Reports First Quarter 2023 Financial Results

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

May 10, 2023, 6:50 AM EDT - 2 years ago

Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)

Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

May 3, 2023, 4:05 PM EDT - 2 years ago

Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023